TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Rein Therapeutics ( (RNTX) ) has issued an update.
On July 23, 2025, Rein Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders, which was previously adjourned on June 24, 2025. During this meeting, stockholders elected William C. Fairey as a Class II director for a three-year term expiring at the 2028 Annual Meeting. Additionally, stockholders approved, on a non-binding advisory basis, the company’s named executive officer compensation.
The most recent analyst rating on (RNTX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.
Spark’s Take on RNTX Stock
According to Spark, TipRanks’ AI Analyst, RNTX is a Underperform.
Rein Therapeutics is experiencing severe financial difficulties, with persistent negative net income and cash flows. The technical analysis suggests bearish momentum with potential near-term volatility. The negative P/E ratio and lack of dividends further highlight the company’s weak financial position. The overall outlook for the stock is challenging, with significant risks outweighing potential rewards.
To see Spark’s full report on RNTX stock, click here.
More about Rein Therapeutics
Average Trading Volume: 38,352
Technical Sentiment Signal: Sell
Current Market Cap: $30.57M
For detailed information about RNTX stock, go to TipRanks’ Stock Analysis page.